Abstract
m-AMSA is an intercalating agent at present on Phase II trial as a chemotherapeutic drug. A 30 min exposure of Chinese hamster (Line V79-753B) cells to submicromolar concentrations of m-AMSA killed 50% of the cells. The survivors had an enhanced sensitivity to radiation-induced cell killing. Depending upon the conditions, m-AMSA enhanced the radiation effect by either a decrease in the survival-curve shoulder or by an increase in slope. m-AMSA may act partly by suppressing the accumulation of sublethal damage but, if so, recovery from damage as measured in split-dose experiments with cells pretreated with the drug is not affected to its radiation effect from selective toxicity to cells in a radioresistant phase of the cell cycle cannot be excluded. Radiation and the drug interacted to give increased cell killing, even when the exposures to each agent were separated in time. It is concluded that m-ASMA may behave like actinomycin D and adriamycin, and enhance clinical radiation responses. in vivo testing to determine the effect of m-AMSA on the therapeutic index is recommended.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Roberts, P., Millar, B. Enhanced killing of mammalian cells by radiation combined with m-AMSA. Br J Cancer 42, 684–691 (1980). https://doi.org/10.1038/bjc.1980.302
Issue Date:
DOI: https://doi.org/10.1038/bjc.1980.302
This article is cited by
-
Effectiveness of AMSA alone or in combination with radiation on murine fibrosarcoma pulmonary nodules
Clinical & Experimental Metastasis (1984)